Skip to main content
Have a personal or library account? Click to login
Azacitidine Treatment in Patients with Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia According to their Cytogenetic Findings Cover

Azacitidine Treatment in Patients with Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia According to their Cytogenetic Findings

Acta Medica Bulgarica
Volume 48 (2021): Issue 3 (October 2021)
By: ,   and    
Open Access
|Oct 2021
Authors

Authors

D. Nikolova

dmb@abv.bg

Department of Medical Genetics, Medical University – Sofia, Bulgaria

A. Yordanov

University Hospital for Active Treatment “Sv. Ivan Rilski” – Sofia, Bulgaria

A. Radinov

University Hospital for Active Treatment “Sv. Ivan Rilski” – Sofia, Bulgaria
DOI: https://doi.org/10.2478/amb-2021-0030 | Journal eISSN: 2719-5384 | Journal ISSN: 0324-1750
Journal RSS Feed
Language: English
Page range: 19 - 25
Submitted on: Jan 29, 2021
Accepted on: Feb 6, 2021
Published on: Oct 22, 2021
Published by: Medical University - Sofia
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Azacitidine (AZA, Vidaza®),
monitoring,
blood count parameters,
toxicity,
cytogenetic findings
Related subjects:
Medicine,
Basic medical science,
Immunology,
Clinical medicine,
Clinical medicine, other

© 2021 D. Nikolova, A. Yordanov, A. Radinov, published by Medical University - Sofia
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 48 (2021): Issue 3 (October 2021)
Previous article
Next article